Amundi’s Anika Therapeutics ANIK Stock Holding History

Amundi’s Portfolio ANIK Stock Details ANIK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-2,005	Closed	-$52.3K	–	2006
2023 Q2	$52.3K	Buy	2,005 +17	+0.9%	+$455	﹤0.01%	1891
2023 Q1	$56.3K	Buy	+1,988	New	+$59.2K	﹤0.01%	1868

Other funds holding ANIK

Trigran Investments Northbrook, Illinois $545M AUM 56.2% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Amundi's ANIK Position: Q3 2023 in Review

Amundi sold out of Anika Therapeutics (ANIK) in Q3 2023, closing a stake of 2,005 shares — an estimated $52.3K sold.

Amundi first reported a position in ANIK in Q1 2023 and held it in 2 quarters. The position peaked at $56.3K in Q1 2023. 115 funds tracked by Wall St. Rank hold ANIK as of Q3 2023.

Amundi reported no remaining Anika Therapeutics position as of Q3 2023 after selling out during the quarter.
Amundi sold 2,005 Anika Therapeutics shares in Q3 2023, an estimated $52.3K.
Amundi first reported a position in Anika Therapeutics in Q1 2023 and held it in 2 quarters.
Amundi's Anika Therapeutics position peaked at $56.3K in Q1 2023.
115 funds tracked by Wall St. Rank held Anika Therapeutics as of Q3 2023.

Based on Amundi's 13F filing for Q3 2023, filed 14 Nov 2023.